Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9603 posts found.

roche__tree

Roche’s Phase 3 Pemphix trial smashes primary endpoint for pemphigus vulgaris

October 14, 2019 Research and Development, Sales and Marketing MabThera, Rituxan, Roche, pharma

Roche has revealed new Phase 3 data demonstrating that its MabThera/Rituxan (rituximab) therapy Pemphix met its primary endpoint in the …
News

Three focus areas to accelerate breakthrough drugs to market

October 11, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing veeva

The number of clinical trials taking place each year continues to rise. In fact, in 2018, the FDA approved a …
Feature
Thought Leadership
jim_greenwood

Biotechnology Innovation Organization Chief to step down after US 2020 elections

October 11, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biotechnology Innovation Organization, US, biotech, pharma

The Biotechnology Innovation Organization (BIO), the largest trade body representing the world’s biotechnology industry, has revealed that its President and …
News
top_10_photo

Top Ten most popular articles on Pharmafile.com this week

October 11, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

It’s the end of the week and time for a rundown of our top most popular articles on Pharmafile these …
News

Bayer UK unveils new Artificial Intelligence ‘LifeHub’

October 10, 2019 Research and Development

Bayer has launched LifeHub UK as part of a network of global innovation hubs designed to accelerate and optimise disease …
News
novo_flag

Novo Nordisk enters into haemophilia gene therapy collaboration

October 10, 2019 Research and Development

Novo Nordisk and bluebird bio have announced they have entered into a three-year research collaboration to jointly develop next-generation in …
News
novartis_side_building

Novartis’ Cosentyx provides sustained resolution of psoriatic arthritis symptoms up to 2 years, data shows

October 10, 2019 Research and Development Cosentyx, Novartis, pharma, psoriatic arthritis

Novartis has unveiled new findings for Cosentyx (secukinumab) which show that the therapy generated “rapid and sustained resolution” of signs …
News
lung_ambition_alliance

The Lung Ambition Alliance: Stronger together

October 9, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Lung Ambition Alliance, lung cancer, pharma

Following our piece by AstraZeneca’s Patrick Connor introducing the Lung Ambition Alliance, a new cross-functional collaboration which aims to double …
Feature

FDA approves Pfenex’s osteoarthritis drug for patients at high risk of fracture

October 9, 2019 Research and Development, Sales and Marketing FDA, Pfenex, osteoporosis, pharma

The FDA has awarded US approval to Pfenex’s drug PF708, it has emerged, as a treatment for osteoporosis in certain …
News
gsk_l_rgb

GSK partners with Lyell Immunopharma to develop cell therapies for cancer

October 9, 2019 Research and Development

GlaxoSmithKline and Lyell Immunopharma have announced a five-year agreement to jointly develop new technologies to improve cell therapies for the …
News
novartis_window

Novartis’ ligelizumab outperforms Roche’s Xolair in chronic urticaria clearance

October 9, 2019 Research and Development Novartis, legelizumab, pharma, urticaria

Novartis has pulled back the curtain on new Phase 2b data for its IgE/FceR1 pathway-blocking drug ligelizumab, showing that the …
News
jj_sign_on_wall

Johnson & Johnson ordered to pay man $8bn over breast growth

October 9, 2019 Research and Development

US pharma giant Johnson & Johnson has been ordered to pay $8 billion in punitive damages to a man over …
News

FDA approves Clinuvel’s Scenesse for rare genetic disorder

October 9, 2019 Research and Development

The US FDA has approved Clinuvel’s Scenesse (afamelanotide 16mg) as the first ever treatment for a rare genetic metabolic disorder …
News
merdad_parsey

Gilead appoints Merdad Parsey as Chief Medical Officer

October 7, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Gilead Sciences have announced that Merdad Parsey will join the company as Chief Medical Officer, effective November 1st. Dr Parsey …
Appointment

Breaking through limits in lung cancer: Introducing the Lung Ambition Alliance

October 7, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Lung Ambition Alliance, feature, lung cancer, pharma

Lung cancer kills more patients than any other variety of cancer, accounting for around a fifth of all cancer-related deaths …
Feature
The Gateway to Local Adoption Series

Latest content

Thermo Fisher opens new distribution centre in Ireland

March 12, 2026

Altimetrik appoints Dhirendra Nath as Chief Human Resources Officer

March 12, 2026

Kindeva appoints Mike Cowhig as Chief Legal Officer

March 11, 2026

DiaMedica gets regulatory clearance from Health Canada for phase 2 preeclampsia study

March 11, 2026

Abselion establishes a US subsidiary in Massachusetts 

March 10, 2026